Uniqure NV (QURE) Announces Plans to Seek UK Approval for AMT-130 Gene Therapy
Uniqure NV (NASDAQ: QURE), a Dutch biotech company, announced its intention to file for regulatory approval of its gene therapy candidate AMT-130 in the UK during Q3 2026. The decision follows positive Phase 1/2 trial data showing a 75% slowing of Huntington’s disease progression at high doses.
Tickers: $QURE
Topics: AMT-130 gene therapy Huntington's disease regulatory approval